Global Blood Therapeutics - GBT Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 11 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBT, but not buy additional shares or sell existing shares.
View GBT analyst ratings or view top-rated stocks.

15 Wall Street research analysts have issued twelve-month target prices for Global Blood Therapeutics' shares. Their GBT share price forecasts range from $31.00 to $75.00. On average, they anticipate the company's stock price to reach $65.32 in the next year. This suggests that the stock has a possible downside of 4.6%.
View analysts price targets for GBT or view top-rated stocks among Wall Street analysts.

Global Blood Therapeutics' stock was trading at $29.27 on January 1st, 2022. Since then, GBT stock has increased by 134.0% and is now trading at $68.49.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GBT earnings forecast.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its quarterly earnings results on Monday, August, 8th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by $0.07. The company earned $71.55 million during the quarter, compared to the consensus estimate of $64.39 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 170.37% and a negative net margin of 137.30%. During the same period last year, the company earned ($1.12) EPS.

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Shares of GBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GBT stock can currently be purchased for approximately $68.49.

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.

The company employs 457 workers across the globe.

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.